Endocyte, Inc.
ECYT
NASDAQ23.99
USD
- -
- -
CIK
0001235007
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Feb 4, 2011
- CIK
- 0001235007
- Similar Companies
- Business
- Endocyte, Inc. operates as a biopharmaceutical company specializing in the development of targeted therapies for cancer and inflammatory diseases in the United States. The company leverages its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents, with core products including Vintafolide, a SMDC in Phase IIb clinical trials for non-small cell lung cancer; EC1456, undergoing Phase I dose escalation trials for advanced solid tumors; and EC1169, a tubulysin-based therapeutic in Phase I trials for advanced metastatic castration-resistant prostate cancer. Additional pipeline products encompass preclinical candidates such as EC2629, a folate receptor-targeted SMDC for cancer treatment; EC2319 for inflammatory diseases; EC0371 for polycystic kidney disease; and a SMDC bi-specific adaptor chimeric antigen receptor (CAR) T-cell therapy targeting cancer immunotherapy. The company also develops radioligand therapies, notably the prostate-specific membrane antigen (PSMA)-targeted 177Lu-PSMA-617, a radioligand in Phase III development for metastatic castration-resistant prostate cancer. Founded in 1996 and headquartered in Indianapolis, Indiana, Endocyte has established strategic alliances and technology collaborations to advance its targeted therapy platform. A major recent development is Endocyte's acquisition by Novartis in 2018 for $2.1 billion in cash, which integrated Endocyte's pipeline and radioligand therapies into Novartis' oncology and nuclear medicine portfolio. This acquisition marked a significant operational change and strategic expansion, enabling Novartis to bolster its radioligand therapy offerings with Endocyte's first-in-class candidates, including 177Lu-PSMA-617, thereby enhancing treatment options for prostate cancer. Post-acquisition, Endocyte's development programs and product pipeline continue to be advanced under Novartis' umbrella, focusing on personalized cancer therapeutics, radioligand therapy, and CAR-T immunotherapy platforms. Endocyte principally serves oncology and inflammatory disease markets through targeted therapeutics that combine precision medicine and molecular targeting. Its technologies encompass small molecule drug conjugates, radioligand therapies, and immuno-oncology, supporting clinical research and development activities primarily in the US with global impact through Novartis. The company is recognized for its innovation in drug conjugation technology that facilitates delivering cytotoxic agents and imaging compounds selectively to diseased cells, supporting personalized cancer treatment and disease management.